According to a recent LinkedIn post from SpliceBio, Chief Medical Officer Aniz Girach, M.D., has been invited to speak at the Annual Retinal Therapeutics Innovation Summit held alongside the ARVO Annual Meeting on May 1 in Denver, Colorado. The summit is co-hosted by Foundation Fighting Blindness and the OHSU Casey Eye Institute, which suggests a forum focused on cutting-edge retinal disease therapies.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post indicates that Girach is expected to discuss progress on SB-007, described as a third-generation intein-based dual AAV gene therapy targeting the genetic cause of Stargardt disease. For investors, this visibility may signal ongoing advancement of SpliceBio’s lead clinical program and could help position the company within the competitive ophthalmic gene therapy space.
Participation in a high-profile scientific summit may also enhance SpliceBio’s credibility with key opinion leaders and potential partners in retinal research. If SB-007 demonstrates compelling clinical data over time, the program could become an important value driver, given Stargardt disease’s unmet medical need and the broader interest in durable gene therapy solutions.